New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
06:20 EDTARAYAccuray buy thesis intact, but delayed, says Jefferies
Jefferies says Accuray's weaker than expected Q2 results and reduced FY13 outlook was not a surprise, but the severity of the downside was a surprise. The firm believes its Buy thesis on the stock remains intact, albeit delayed, and lowered its price target for shares to $6.50 from $10. Jefferies keeps a Buy rating on Accuray.
News For ARAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
07:31 EDTARAYAccuray announces first patient treatment using CyberKnife M6 completed
Accuray announced that the first patient treatment has been completed using the CyberKnife M6 System with the InCise Multileaf Collimator. The treatment was administered as a multidisciplinary effort between Dr. Steven Burton from the Department of Radiation Oncology and Dr. Johnathan Engh from the Department of Neurosurgery at UPMC in Pittsburgh, Pennsylvania. UPMC was one of the InCise MLC evaluation sites working in collaboration with Accuray.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use